|
US6576754B2
(en)
|
1995-11-09 |
2003-06-10 |
Dana-Farber Cancer Institute |
CD100 antigen and uses therefor
|
|
EP1442749A1
(en)
*
|
2003-01-31 |
2004-08-04 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
|
|
HRP20140049T1
(hr)
|
2007-01-05 |
2014-02-28 |
University Of Zürich |
Anti beta-amiloid antitijela i njihova upotreba
|
|
US7919594B2
(en)
|
2007-02-14 |
2011-04-05 |
Vaccinex, Inc. |
Human anti-CD100 antibodies
|
|
PT3002298T
(pt)
|
2007-11-21 |
2019-11-20 |
Univ Oregon Health & Science |
Anticorpos monoclonais anti-fator xi e métodos de utilização dos mesmos
|
|
AU2009328505B2
(en)
|
2008-12-19 |
2014-11-27 |
Panima Pharmaceuticals Ag |
Human anti-alpha-synuclein autoantibodies
|
|
ES2647823T3
(es)
|
2009-05-08 |
2017-12-26 |
Vaccinex, Inc. |
Anticuerpos anti-CD100 y métodos de uso de los mismos
|
|
AU2011295902B2
(en)
|
2010-09-02 |
2014-12-04 |
Vaccinex, Inc. |
Anti-CXCL13 antibodies and methods of using the same
|
|
HUE041391T2
(hu)
|
2011-06-23 |
2019-05-28 |
Biogen Int Neuroscience Gmbh |
Anti-alfa-szinukleinkötõ molekulák
|
|
BR112014008885B1
(pt)
|
2011-10-11 |
2021-02-17 |
Vaccinex, Inc |
uso de um anticorpo isolado ou fragmento de ligação ao antígeno do mesmo que se liga especificamente à semaforina-4d para diminuir permeabilidade da barreira hematoencefálica (bbb) em um indivíduo com permeabilidade da bbb aumentada e um transtorno neuroinflamatório
|
|
US20140295465A1
(en)
|
2011-11-02 |
2014-10-02 |
Biogen Idec International Neuroscience Gmbh |
USE OF AN ANTI-alpha-SYNUCLEIN ANTIBODY TO DIAGNOSE AN ELEVATED LEVEL OF alpha-SYNUCLEIN IN THE BRAIN
|
|
US8790652B2
(en)
|
2011-12-06 |
2014-07-29 |
Vaccinex, Inc. |
Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
|
|
NZ629828A
(en)
|
2012-03-02 |
2017-05-26 |
Vaccinex Inc |
Methods for the treatment of b cell-mediated inflammatory diseases
|
|
US9090709B2
(en)
|
2012-03-28 |
2015-07-28 |
Vaccinex, Inc. |
Anti-SEMA4D antibodies and epitopes
|
|
US10494440B2
(en)
|
2012-05-11 |
2019-12-03 |
Vaccinex, Inc. |
Use of semaphorin-4D binding molecules to promote neurogenesis following stroke
|
|
EP2951204B1
(en)
|
2013-01-31 |
2019-05-22 |
Vaccinex, Inc. |
Methods for increasing immunoglobulin a levels
|
|
BR112015021964A2
(pt)
|
2013-03-08 |
2017-08-29 |
Vaccinex Inc |
Anticorpo isolado ou um fragmento ligante de antígenos do mesmo que se liga especificamente a cxcl13, composição e seus usos
|
|
MX377858B
(es)
|
2013-06-25 |
2025-03-11 |
Vaccinex Inc |
Combinación de moleculas inhibidoras de semaforina-4d con agentes inmunomoduladores y usos de los mismos.
|
|
NZ630881A
(en)
|
2013-10-10 |
2016-03-31 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for treatment of atherosclerosis
|
|
NZ630892A
(en)
|
2013-10-21 |
2016-03-31 |
Vaccinex Inc |
Use of semaphorin-4d binding molecules for treating neurodegenerative disorders
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
KR102261618B1
(ko)
|
2015-03-31 |
2021-06-04 |
메디뮨 리미티드 |
신규한 il33 형태, il33의 돌연변이된 형태, 항체, 검정 및 이의 이용 방법
|
|
CN110325547B
(zh)
|
2016-11-07 |
2023-12-26 |
德格克斯有限公司 |
新淀粉样蛋白β寡聚体特异性结合分子
|
|
BR112019019597A2
(pt)
|
2017-03-20 |
2020-04-14 |
Vaccinex Inc |
tratamento de câncer com um anticorpo anti-semaforina- 4d em combinação com um agente de modulação epigenética
|
|
WO2018204895A1
(en)
|
2017-05-05 |
2018-11-08 |
Vaccinex, Inc. |
Human anti-semaphorin 4d antibody
|
|
IL272773B2
(en)
|
2017-08-22 |
2024-06-01 |
Biogen Ma Inc |
Pharmaceutical preparations containing anti-amyloid cell antibodies
|
|
MX2021011799A
(es)
|
2019-03-28 |
2021-10-26 |
Vaccinex Inc |
Antagonistas de semaforina 4d para usarlos en la terapia contra el cancer.
|
|
EP3986446A1
(en)
|
2019-06-21 |
2022-04-27 |
Vaccinex, Inc. |
Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
|
|
CA3152371A1
(en)
|
2019-08-01 |
2021-02-04 |
Vaccinex, Inc. |
Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor
|
|
US11597765B2
(en)
|
2020-06-25 |
2023-03-07 |
Vaccinex, Inc. |
Use of semaphorin-4D binding molecules for the treatment of Rett syndrome
|
|
IL311639A
(en)
|
2021-09-27 |
2024-05-01 |
Vaccinex Inc |
Predictive outcome profile for the use of an anti-semaphorin-4D binding compound for the treatment of neurodegenerative diseases
|
|
US20230331863A1
(en)
|
2022-02-13 |
2023-10-19 |
Vaccinex, Inc. |
Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease
|
|
WO2026030311A1
(en)
|
2024-07-29 |
2026-02-05 |
Vaccinex, Inc. |
Use of semaphorin-4d inhibitory molecules to treat cognitive impairment
|
|
WO2026080818A1
(en)
|
2024-10-10 |
2026-04-16 |
Vaccinex, Inc. |
Use of anti-semaphorin-4d inhibitory molecules in combination with flt3 ligand to inhibit tumor growth and metastasis
|